TFF Pharmaceuticals And Leidos To Advance Next-Generation Biodefense Countermeasures Under DARPA Personalized Protective Biosystems Program into Preclinical Testing
- The Leidos team's Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company's Proprietary Thin Film Freezing Technology.
- MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models.